Schrödinger announced collaboration with Bristol Myers Squibb to discover, develop, and commercialize therapeutics in multiple disease areas, according to the company’s press release. The multi-year collaboration combines Schrödinger’s leading physics-based computational platform and drug discovery capabilities with Bristol’s expertise in development and commercialization.
- The Schrödinger-Bristol Myer collaboration seeks to advance small molecule therapeutics targeting oncology, immunology, and neurological disorders, capitalizing on each company’s expertise
- The collaboration includes two of Schrödinger’s early-stage programs and additional undisclosed targets.
- Schrödinger will lead in the discovery of development candidates for each of the targets under the collaboration.
- Bristol Myers will be responsible for the development, manufacturing, and commercialization of the development candidates.
Schrödinger is gaining as Bristol Myers loses. SDGR: NASDAQ is up 12.97%, BMY: NYSE is down 0.60%